News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arvinas Inc.
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
NVS
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
NVS
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
NVS
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Chief Financial Officer Transition
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.